NEWARK, DE — N-Zyme Biomedical has begun a Phase 2 clinical trial of its lead drug candidate for laryngopharyngeal reflux, advancing a treatment approach that targets pepsin rather than stomach acid in a market where many patients continue to experience symptoms despite existing therapies.
The clinical-stage biotechnology company is evaluating a pepsin inhibitor based on fosamprenavir, a previously approved compound with an established safety profile. The study will assess the therapy’s safety and effectiveness in patients diagnosed with laryngopharyngeal reflux, commonly known as LPR or “silent reflux.”
The trial marks a development milestone for N-Zyme’s effort to commercialize what it describes as a new class of reflux therapeutics. Current standard treatments, including proton pump inhibitors, focus primarily on suppressing stomach acid but do not directly address non-acidic components of reflux…